Project to renovate Chinese fishing nets on Fort Kochi beach in limbo
About a decade since its inception, the ₹2.40-crore project of Kerala Tourism to renovate the iconic Chinese fishing nets along the Fort Kochi beachfront remains in limbo, with only four of the nets being renovated.
The teak logs that were procured over four years ago for the purpose can be seen abandoned on the beach walkway. Although Kerala Tourism officials say it may take up to November to renovate the rest of the seven nets, those operating the nets are confident that this can be done by August, prior to the commencement of the tourist season, if funds are provided.
Expressing concern at the delay in sanctioning funds, including to procure fishing nets for the project, Sebastian Kurisinkal, president of the Chinese Nets Owners' Association, say most of the owners and workers are struggling to make ends meet, faced with uncertainty about the renovation of the nets.
'They earn a pittance due to the steep fall in fish catch and sea incursion on the beachfront. They have still not been paid their dues, despite the labour they put into renovating the nets. Both Kerala Tourism and KITCO, the project implementing agency, must take steps to hand over the requisite funds,' he says.
Over time, most of the net operators had replaced the damaged teak logs that support the nets with iron pipes, at the cost of aesthetics of the Chinese nets, due to delay in sourcing forest teak logs of similar length.
Pointing to the need to replace the ageing iron pipes, Mr. Kurisinkal says workers trained in replacing the logs and the wooden stumps of the nets often fail to turn up following the delay in releasing funds.
A Kerala Tourism official said a committee headed by K.J. Maxi, MLA, was overseeing the renovation process, considering the role they played during the past decades in wooing tourists. 'It is hoped that the Finance department clears the pending bills so that the renovation of the nets can be completed in six months,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
29 minutes ago
- Mint
Cost pinch is coming for cement companies in Q1
The early onset of the monsoon plays spoilsport for cement demand and prices. Also, a temporary rise in power and fuel costs (P&F) is on the cards for cement makers in the June quarter (Q1FY26). The cost of imported petroleum coke (pet coke) saw a sudden spike in March. A surge in demand by Chinese companies in anticipation of higher tariffs led to pre-booking, which translated into higher procurement costs. P&F costs are estimated at 30-35% of the cement sector's total production cost. Petcoke, which is derived from oil refining, is a key input material for cement manufacturers. Typically, cement companies import petcoke and stock fuel inventories for two-three months. So, the impact on profitability due to movement in fuel costs comes with a lag. Although spot international petcoke cost has now cooled off to $104/tonne from around $122/tonne in March, cement companies with a relatively higher reliance on this fuel could feel the heat in Q1FY26. Also read: Meta in talks to invest nearly $10 billion in artificial intelligence startup Scale AI 'On average, this should translate into a P&F cost/tonne increase of ₹75 for Indian cement companies during Q1FY26 on a sequential basis. North-focused cement makers Shree Cement Ltd and JK Cement could be most hurt," said Kunal Shah, analyst at DAM Capital. The fuel mix of Shree Cement and JK Cement comprises 95% and 70% petcoke, respectively. On the other hand, UltraTech Cement Ltd should be least affected given material exposure to imported coal, where cost trends were favourable in Q4FY25, he added. (See chart 1) To counter fuel cost volatility and reduce carbon footprint, cement companies have been enhancing their cost efficiency by investing in green energy and waste heat recovery systems. For instance, Ambuja eyes cost savings of ₹500-550/tonne by FY28 and has achieved around ₹150-170/tonne in FY25. Further savings of ₹100/tonne is likely in FY26. Dalmia Bharat Ltd expects to meet half of its ₹150–200/tonne cost savings target in FY26. These are steps in the right direction, but they would yield outcomes gradually. Cement prices However, in the current backdrop, if cement prices sustain at higher levels, companies could get some cushion from this cost bump. In June so far, cement prices in the trade segment at pan-India level are up by ₹2/bag month-on-month to ₹358/bag, according to Nomura Global Markets Research. One cement bag weighs 50kg. This is largely led by a ₹19/bag hike in the south, although cement prices are marginally down by ₹2-5/bag in other regions. In Q1FY26 so far, the average pan-India trade segment cement price is up ₹12/bag sequentially to ₹356/bag, the Nomura report said on 4 June. The brokerage cautions that pricing indiscipline amid industry consolidation will likely keep trade prices range-bound. Also read: Policy U-turn? New govt notice hints at easier local sourcing rules for telecom equipment makers Dealer channel checks by brokerages show that cement demand has been in the low single digits in Q1FY26 so far. Q1 will be followed by a seasonally weak Q2 as construction activities tend to be dull during the monsoon season. So, depending upon the pace of demand recovery, any meaningful improvement in cement prices could happen in H2FY26. Large cement stocks have given mixed returns in 2025 so far. On a one-year forward EV/Ebitda, the sector is trading at a valuation multiple of 20.6x, which is around a 25% premium to the long-term average, according to Motilal Oswal Financial Services. The sector's valuation declined around 30% by March 2025 from its peak in June/July 2024 due to weaker-than-estimated demand growth, continuing pricing pressure, and an increase in fuel prices, it said in a report. For rich valuations to justify realisations, they have to meaningfully improve. Key takeaways Also read: Not Ozempic, in India THIS weigh-loss and diabetes drug from Eli Lilly sees sales jump 60% — what is it?
Mint
an hour ago
- Mint
Centre to introduce minimum import price on pharmaceutical raw materials to curb cheap Chinese imports
New Delhi: India plans to introduce a minimum import price (MIP) for select pharmaceutical raw materials in a move to shield its domestic industry from a flood of cheap Chinese imports, two people directly involved in the process said, a step that will also shore up India's status as the world's largest supplier of generic drugs. India accounts for about 20% of the global supply of generic drugs and manufactures about 60,000 generic brands, across 60 categories. The plan comes against the backdrop of the Centre's move to bulk up its Production Linked incentive (PLI) scheme for generic drugs by including more molecules used in manufacturing key starting materials (KSMs), drug intermediates, and Active Pharmaceutical Ingredients (APIs). KSMs and intermediates are chemical compounds used to synthesize APIs, which are the main components of a drug. 'The government is working on a plan to impose a minimum import price on all PLI based pharmaceutical products. The plan is to protect the domestic industry so that they are able to continue to do the business and to make India self-reliant," said one of the two people mentioned above. The measure seeks to build on India's recent success with domestic production of critical antibiotics such as Penicillin G. The API industry is a crucial segment of the pharmaceutical sector, accounting for about 35% of the market. However, India is dependent on imports for 80% of its bulk drug requirement. Bolstering self reliance The move also aims to bolster India's goal of self-reliance in the pharmaceutical sector. The heavy reliance on China, the world's largest producer and exporter of APIs, creates significant risks for India's medicine supply chain. In 2021, the government launched the ₹15,000 crore PLI scheme for the pharmaceuticals sector. There are about 500 API manufacturers in India, which account for about 8% of the global API industry. In addition, the production of APIs for essential medicines is also promoted through a dedicated PLI scheme for bulk drugs, KSMs and APIs. The government is seeking new applications as the previous iteration of the PLI scheme failed to meet the expectations due to dumping of cheap commodities from China. Also read | India curbs exports of 13 key pharma ingredients These schemes are aimed at protecting and encouraging domestic ingredient manufacturing which is seen as a critical step in securing the future growth and stability of India's pharma sector. According to the second person, the plan is a direct response to appeals from the domestic API industry, which has struggled to compete with the low prices of Chinese products. 'Actually, industry needs protection like some anti-dumping measures and MIP to make India self-reliant," the second person said, referring to a practice where a country 'dumps' its exports in other countries at prices that are less that what it costs to make these goods. Exports marginally higher As per commerce ministry data, India recorded a modest trade surplus in bulk drugs and intermediates in FY25, with exports totalling $4.90 billion and imports at $4.64 billion. In FY24, exports stood at $4.79 billion, slightly ahead of imports worth $4.56 billion, again resulting in a surplus. Similarly, in FY23, exports were $4.77 billion compared to imports of $4.51 billion, continuing the trend of a positive trade balance in this segment. The Indian Drugs Manufacturers' Association (IDMA) called for a cautious and data-driven approach to the proposal for imposing minimum import prices on select APIs and KSMs. The industry body has warned the government against a blanket application of the trade measure. 'We believe that a data-backed, well-studied and balanced approach should be considered," said Viranchi Shah, national spokesperson for IDMA. While the move is intended to discourage cheap imports and support the domestic pharma industry, Shah cautioned that India's strong position in finished formulation exports must not be compromised. Also read | India seeks financial details of pharmaceutical marketing practices 'The minimum import price should not come as a blanket strategy across the board, considering that India also has a very strong formulation industry," he said. 'Our industry has to remain competitive both domestically and globally." IDMA reiterated its support to the government's self-reliance push under the 'Atma-Nirbhar Bharat" campaign but urged policy planners to ensure that trade interventions like MIP do not end up hampering Indian exports by making them more costly. Queries sent to the spokespersons of India's commerce ministry, and department of pharmaceuticals on Friday and the Embassy of China in New Delhi on Saturday remained unanswered till the press time. China dependent Ajay Srivastava, co-founder of the Global Trade Research Initiative (GTRI), a policy think tank, said India's chemicals and pharmaceuticals sector—which plays a crucial role in healthcare, agriculture, and industry—is becoming heavily dependent on imports from China. 'This growing reliance not only exposes India to supply chain vulnerabilities but also raises significant strategic concerns, especially in the current global climate where geopolitical tensions and trade disruptions are increasingly common. Strengthening domestic production is thus not just an economic priority but a national security imperative," he said. A GTRI report from April 2024 states that India's imports of chemicals and pharmaceuticals reached $54.8 billion in FY2024. Between 2007 and 2022, China's share in these imports rose sharply from 18% to 29%, with imports from China increasing nearly fourfold—from $4.4 billion to $17.4 billion. Also read | Bitter pill for Indian pharma as Trump tariffs could hurt exports by $2.25 bn Although imports from other countries has also ballooned, the heavy dependence on China remains a major strategic concern. In 2022, India's chemical and pharmaceutical imports totaled $76.94 billion, with China accounting for 26.8%, followed by Saudi Arabia, the US, Japan, and Russia. There has been a notable increase in antibiotic imports from $551.2 million in 2007-10 to $1.27 billion in 2020-22, an increase of 130.7%. Here too, China's market share climbed to 81.7%, underscoring a high dependency on Chinese pharmaceutical products essential for addressing widespread public health needs in India, it said. Instrument of control A minimum import price is an instrument used by countries to control surplus imports. As a case in point, India has used MIPs to curb the import of steel and agricultural products like onions and pulses. By filtering out extremely low-cost imports, MIP also helps maintain quality standards, ensuring that only manufacturers capable of meeting cost-based compliance and quality norms supply APIs to the Indian market. 'While such a measure could lead to a short-term increase in input costs for drug makers dependent on Chinese supplies, it is seen as a necessary step for strengthening the domestic pharmaceutical ecosystem and reducing strategic vulnerabilities," said Abhash Kumar, a trade economist and assistant professor of economics at Delhi University. Also read | India eyes Asean to boost pharma exports An MIP is not outright banned under WTO rules, but it can face challenges if used unfairly or for extended periods. The WTO also allows rules-based instruments like tariffs or anti-dumping duties backed by formal investigations. India imposed an MIP on steel in 2016, but later replaced it with WTO-compliant remedies like safeguard duties.
Time of India
2 hours ago
- Time of India
Auto companies seek govt help for magnet imports
NEW DELHI: The automobile industry has sought govt support in expediting approvals from the Chinese govt for importing rare earth magnets used in various applications, including passenger cars. As per sources, various domestic suppliers have already sought approval from the Chinese govt through their local vendors in China. However, no approvals have been granted so far, sources said. China controls over 90% of global processing capacity for the magnets, used across multiple sectors including automobiles, home appliances and clean energy. The Chinese govt has put restrictions, with effect from April 4, mandating special export licences for seven rare earth elements. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
